Abstract

as the immunomodulatory drugs typically used for MS will beineffective for relapse prevention in NMO and severe refractoryattacks in NMO usually necessitate rescue plasmapheresis or moreeffective immunosuppressive therapies [3].In the management of this suspected case of NMO, the authorsmade use of investigatory tools such as cerebrospinal fluid analysisand MRI of the brain/spinal cord in diagnosis. However, asindicated by de Seze et al. [2], even when all these investigatoryarmaments are summoned there is still the pitfall of misdiagnosisand the inability to distinguish the two. Recently, using thetechnique of dual immunostaining, Lennon et al. [4] havedemonstrated that a serum autoantibody marker, NMO-IgG,is highly specific for neuromyelitis optica and can significantlycurtail the diagnostic ambiguity.Perhaps, with the aid of a specific autoantibody marker, themanagement of this patient might have been more streamlined.The authors have declared no conflicts of interest.A. Y. K. C

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call